Leading and Innovating in Virology

What We Have Accomplished

For decades, we have led global virology research, turning once-fatal diseases into manageable or more easily preventable conditions.

From pioneering the first HIV single-tablet treatment regimen to launching an innovative long-acting prevention option, we are setting new milestones in prevention and care with therapies that aim to significantly improve outcomes for people and communities affected by HIV.

In hepatitis, we developed a cure for hepatitis C, and our therapies helped transform hepatitis B into a more manageable condition. And when the world needed us, we stepped up to deliver the first approved antiviral medicine to treat COVID-19.

These advances were possible thanks to our investment in world-class science, our deep connections with community partners and our long-standing commitment to advancing health and opportunity to all.

Our Current Focus

Today, we’re building on our legacy in virology, developing long-acting and person-centered options for HIV prevention and treatment while working together with community partners to help end the epidemic. At the same time, we're developing new treatments for chronic hepatitis B and D as we work toward the global elimination of hepatitis as a public health threat.

Looking Ahead

We won’t rest until the HIV epidemic has ended for everyone, everywhere. Ultimately, we're working to help develop cures for HIV and hepatitis B, while advancing our preparedness against potential infectious diseases.

At the same time, we recognise that medicines alone won’t lead to the healthier world we envision. We’re committed to working closely with partners to advance health equity and break down the barriers to care that fuel the spread of viruses and affect access to care.

Oncology:
Cancer steals possibility. We're taking it back.

Innovation

Gilead and Kite Oncology are working to transform how cancer is treated. We’re innovating with next-generation therapies, combinations and technologies to deliver improved outcomes for people with cancer. Our bold approach is redefining cancer research by accelerating development of therapies and potential cures.

Scientific Framework

We’re purposefully building our oncology portfolio and pipeline to address the greatest gaps in care. From antibody-drug conjugate technologies and small molecules to cell therapy-based approaches, we're relentlessly committed to creating transformative therapies for people with cancer. Our oncology pipeline focuses on three biological strategies:

• Killing cancer cells from within
  We develop therapies that selectively target and kill cancer cells with minimal impact on healthy tissue.
• Engaging the immune system to fight cancer
  We advance innovative approaches, like small molecules, therapeutic antibodies and cell therapies, that reprogram and stimulate the body’s own immune cells to recognize and eliminate cancer cells.
• Disrupting the tumor microenvironment that enables cancer to grow
  We develop therapies that disrupt the support network of cancer cells, allowing the body’s immune system and anti-cancer agents to work more effectively.

Innovating to Advance Care for Inflammatory Disease

Pursuing Next-Generation Therapies

Effective therapies are needed to treat inflammatory and fibrotic diseases. Even with recent advances, many people still have few treatment options and continue to experience symptoms and disease progression.

We believe long-term remission, or in some cases, a cure, is possible for many of these diseases despite the challenges they present. We’re leveraging our past successes and learnings and applying them to our research today — with the hope of bringing effective therapies to as many people as possible.

Leveraging Our Expertise

Our advanced immunology research is unlocking next-generation therapies for inflammatory and fibrotic diseases such as primary biliary cholangitis (PBC), inflammatory bowel disease, and lupus.

Leveraging our network of partnerships and extensive expertise in immunology, we're advancing a range of programs to help address these chronic conditions and the toll they take on patients’ lives.

Our Scientific Approach

Chronic inflammatory and fibrotic diseases are often characterized by a vicious cycle of tissue damage, immune response and fibrosis (scarring) that leads to organ damage and disease progression over time. Our programs focus on disrupting that cycle through four different methods, which we call our BETR framework:

• Blocking immune activation
• Eliminating pathogenic cells
• Tolerizing immune response
• Restoring function & promoting regeneration